🔎 Trials Near Me

Hjem › Steatotisk leversykdom › Texas › San Antonio

Kliniske studier for Steatotisk leversykdom i San Antonio, TX

17 studier for Steatotisk leversykdom søker deltakere på steder i og rundt San Antonio (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

RekruttererFase 3
  • 89bio Clinical Study Site, San Antonio
  • 89bio Clinical Study Site, San Antonio
  • 89bio Clinical Study Site, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06419374

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

RekruttererFase 3
  • 89bio Clinical Study Site, San Antonio
  • 89bio Clinical Study Site, San Antonio
  • 89bio Clinical Study Site, San Antonio
  • og 2 flere
Alder 18 til 80 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06318169

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

RekruttererFase 3
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07704892

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

RekruttererFase 3
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07701993

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

RekruttererFase 2
  • American Research Corporation at The Texas Liver Institute, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07527910

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

RekruttererFase 2
  • American Research Corporation at The Texas Liver Institute, San Antonio
  • Pinnacle Clinical Research - San Antonio, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05519475

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

RekruttererFase 3
  • American Research Corporation at Texas Liver Institute, San Antonio
  • Clinical Trials of Texas, LLC dba Flourish Research, San Antonio
  • IMA Clinical Research San Antonio, San Antonio
  • og 1 flere
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

RekruttererFase 3
  • Akero Clinical Study Site, San Antonio
  • Akero Clinical Study Site, San Antonio
  • Akero Clinical Study Site, San Antonio
  • og 2 flere
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

RekruttererFase 3
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07221188

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

RekruttererFase 2
  • Quality Research, Inc., San Antonio
  • Pinnacle Clinical Research - South San Antonio, San Antonio
  • Pinnacle Clinical Research, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07288138

Quantifying Hepatic Mitochondrial Fluxes in Humans

RekruttererFase 4
  • Texas Diabetes Institute - University Health System, San Antonio
  • University of Texas Health Science Center at San Antonio, San Antonio
Alder 18 til 80 · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05305287

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

RekruttererFase 2
  • GSK Investigational Site, San Antonio
Alder 18 til 70 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06613698

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

RekruttererFase 3
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT07221227

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

RekruttererFase 2
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 8. jul. 2026 · NCT06920043

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

RekruttererFase 1
  • GSK Investigational Site, San Antonio
Alder 18 til 70 · Alle kjønn · Oppdatert 9. jun. 2026 · NCT07358546

Evaluating the Pharmacokinetics and Safety of Miricorilant

RekruttererFase 1
  • Site# 433, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 26. mai 2026 · NCT07553663

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

RekruttererObservasjonsstudie
  • Endeavor Clinical Trials, San Antonio
Alder 18 til 75 · Alle kjønn · Oppdatert 14. aug. 2025 · NCT07122700

Steatotisk leversykdom-studier i andre byer

Andre studier i San Antonio

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.